chevron_leftBack
As of 13 June 2026, Novavax, Inc. has a market cap of $1.3B USD, ranking #9247 globally and #1992 in the United States.
It ranks #786 in the Healthcare sector, and #153 in the Biotechnology industry.
Key Stats
Market Cap
$1.3BUSD
Enterprise Value
$844.01MUSD
Revenue (TTM)
$1.12BUSD
EBITDA (TTM)
$590.85MUSD
Net Income (TTM)
$440.3MUSD
EBITDA Margin
53%
Profit Margin
39%
PE Ratio
3.1
PS Ratio
1.2
EV/EBITDA
1.4
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
John Jacobs
open_in_new
Employees
749
Founded
1987
IPO
05 Dec 1995
Website
novavax.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.6% | -5.7% | -5.7% | -14% | -6.5% | 19% |
News
Loading...
NVAX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
NVAX
Novavax Inc
ISIN: US6700024010
Shares Out.:
Shares Outstanding:
164.438M1
Shares Float:
156.183M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
7.97 USD | |
|
0A3S
Novavax Inc
ISIN: US6700024010
|
7.96 USD | |
|
NVAX
Novavax Inc
ISIN: US6700024010
|
6.78 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Novavax, Inc.
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
14K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
12K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
2K%
|
-
|
|
NYSE: IQV
|
$26.3B
2K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
2K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
1K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
4K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
3K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
3K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
3K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
2K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
2K%
|
-
|
chevron_leftBack